
Unite Health Systems With Community-led Health Services To Deliver On UHC
We cannot deliver on universal health coverage (UHC) unless we reach the unreached people with standard health services – with equity and human dignity. Uniting Health systems with Community-led health services should be the new lens to look at UHC.
Despite mounting evidence of how key population or community-led health services have bridged the gap between public health system and those unreached, we are yet to optimally integrate community-led health service delivery model into public health system effectively, said Dr Nittaya Phanuphak.
Dr Nittaya Phanuphak is the Executive Director of Institute for HIV Research and Innovation (IHRI), Governing Council member of International AIDS Society (IAS), and Convener of 2nd Asia Pacific Conference on Point-of-Care Diagnostics for Infectious Diseases.
Sterling examples of high impact key population or community-led health service deliver models come from the land of smiles – Thailand. HIV key populations continue to play a major role in delivering Pre-Exposure Prophylaxis (PrEP for HIV prevention) to those who are at a heightened risk of HIV acquisition. Thailand has the largest PrEP rollout in Asia Pacific region, 80% of people using PrEP in Thailand receive it from a clinic led and staffed by members of the community that it serves. Key populations are groups of people who are disproportionately affected by HIV (which includes gay men and other men who have sex with men, transgender women and sex workers).
'On the ground, despite successes, we have faced challenges too over the last decade in our efforts to integrate community-led health service delivery model into the national public health system in Thailand. Key population lay providers are still the main providers and carers who are initiating and maintaining key population clients in PrEP services,' said Dr Phanuphak.
Over two years ago, Thai government changed regulations which adversely impacted the community-led health services. For example, due to these regulatory changes by the government, PrEP medications were not allowed to be stocked at the clinics run by key populations. Key population service providers were only allowed to give PrEP if it was prescribed by government doctors (and not NGO doctors).
'These regulations are still there but, on the ground, we are upholding our core values of delivering health services in a people-centred way. Many public hospitals work closely with key population led clinics since more than a decade now. These hospitals have seen the impact of key population led health services at the provincial level. They too feel that the best way forward is to continue and maintain the original flow of having client come to the key population led clinics, get tested for HIV by lay providers, and then have the PrEP prescription made through TeleHealth by a government doctor. PrEP can be given out to the client within an hour of entering the clinic,' said Dr Phanuphak.
Funding cuts have made community-led services even more vital
Trump's decisions have snapped funding majorly to a range of health-related projects in the Global South. Dr Nittaya opines that with limited resources it becomes even more critical to ensure we are serving those most in need and most likely to be left behind.
'We need to continue integrating key population led health services into country's healthcare system and make sure that key population led clinics are receiving their reimbursements from the government in a fair way. We also need to ensure that the cadres of lay providers are recognised and endorsed at the country level,' said Dr Nittaya Phanuphak.
Community-led services are not just limited to HIV
'Key population or community-led health services is not only limited to HIV services. It can also be expanded to services for sexually transmitted infections (STIs), mental health, harm reduction, among others. This would be a real game changer for public health in Thailand,' said Dr Phanuphak.
Other countries in southeast Asian and western pacific region such as the Philippines, Viet Nam, Myanmar, and Laos, are also following Thailand-model by adapting community-led health services in their own unique in-country contexts and realities.
Communities and countries need to learn from each other too, says Dr Nittaya Phanuphak. 'We learn from the Philippines that there are members of key populations within the healthcare providers including medical professionals. In Viet Nam, we are seeing a good role of private sector in developing key population led clinics – many of which are social enterprise models too.'
End delays in translating scientific breakthroughs into public health impact
Among the biggest breakthrough scientific announcements in 2024 was lenacapavir - a medicine (twice yearly injections) that showed 100% protection against HIV among women who took part in the study. The study called PURPOSE-1 had cisgender women as participants and lenacapavir demonstrated 100% efficacy in preventing HIV infection. PURPOSE-2 study enrolled a more diverse population of cisgender men, transgender men, transgender women and non-binary individuals who have sex with partners assigned male at birth. PURPOSE-2 study results showed that twice-yearly lenacapavir cut HIV incidence by 96%.
Dr Nittaya Phanuphak shares her disappointment because when the HIV prevention medicine lenacapavir was announced last year, she was rightly hoping for a rapid rollout to protect many more people from HIV acquisition. But it has not happened so far.
"Despite the progress over the last 2-3 decades in HIV response, we still had 1.3 million people who were newly diagnosed with HIV in 2023 worldwide. Around a quarter of these new infections occurred in Asia Pacific region. We have HIV prevention tools in our region but pace at which these are being rolled out is not acceptable. No one needs to get newly infected with HIV because we have the science-based tools to prevent the transmission. For example, PrEP rollout is barely 2% of the target rollout for 2025 (target was to ensure that at least 8.2 million people have used PrEP at least once in a year by end of 2025). This is a huge gap," she said.
Unless all science-based new and old HIV prevention tools would not be offered to people to choose from, we would not be able to protect everyone from the virus.
"When research and development of these new health technologies have taken place in our countries in the Global South so that we can have enough scientific evidence for approvals from US FDA or European Medicine Agency, then why cannot people of our own countries access these approved products?" asks Dr Phanuphak. "This is not fair."
Deploying health technologies developed by the Global South equitably at the point-of-need
Dr Phanuphak calls for uniting our community power in the Global South and leverage upon our regional purchasing power to negotiate lowest possible prices for quality assured screening and diagnostic tools and generic medicines - especially those developed in the Global South. She also underlines the importance of taking services for multiple diseases and health conditions to the communities in people-centred and rights-based manner.
She says that when a health technology is approved by the regulators, it should be developed and made accessible to the people in the Global South without any delay. Not doing so, is not acceptable.
1st Asia Pacific Conference on Point-of-Care Diagnostics for Infectious Diseases was held in Australia. Dr Phanuphak was among those who worked hard to bring the 2nd POC 2025 to Thailand which will be held during 19-21 June 2025 with her being its convener.
She rightly calls for deploying scientifically validated point-of-care health tools closer to the communities to strengthen multiple disease responses, such as for TB, HIV, STIs, vector-borne diseases like malaria or dengue, hepatitis, HPV, among others.
She calls for accelerating innovations in developing more health technologies to serve the most-in-need communities in a rights-based, gender transformative and people-centred manner. "Point-of-care technologies is not only limited to testing for example, but also point-of-care sample collection tools too, so that sample collection not only gets enhanced but also it can be done in a way that it becomes self-care. We should not have to rely on people going to healthcare facilities for sample collection by healthcare providers, but if science-based tools become available, then sample collection can perhaps be done by the clients themselves and sent to the nearest testing centre."
"We cannot talk about new point-of-care technologies without talking about game-changing health financing, policies and political commitment too. At the POC 2025, I hope that we can bring all these aspects together so that we can not only transition in deploying point-of-care health technologies where they are needed most in people-centred manner, but also how can we sustain the implementation," she said.
Integration may not mean the same for everyone
Dr Phanuphak reflects that integration may have different meanings for different people. "A programme manager may think of integrating services together, such as those for TB and HIV. For grant managers it may mean integrating testing platforms, such as those for TB and HIV. We have seen on the ground already that community-led clinics have naturally integrated HIV, hepatitis and STIs services to serve people better. Lay providers have also gone beyond the laboratory integration by integrating mental health, harm reduction, social and legal services."
She calls for reimagining integration in a people-centred way so that we can deliver on WHO Multi-Disease Elimination Approach at the local level and scale up those that have demonstrated impact.
Shobha Shukla – CNS (Citizen News Service)
(Shobha Shukla is the award-winning founding Managing Editor and Executive Director of CNS (Citizen News Service) and is a feminist, health and development justice advocate. She is a former senior Physics faculty of prestigious Loreto Convent College and current Coordinator of Asia Pacific Regional Media Alliance for Health and Development (APCAT Media) and Chairperson of Global AMR Media Alliance (GAMA received AMR One Health Emerging Leaders and Outstanding Talents Award 2024). She also coordinates SHE & Rights initiative (Sexual health with equity & rights). Follow her on Twitter @shobha1shukla or read her writings here www.bit.ly/ShobhaShukla)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Scoop
a day ago
- Scoop
Legalising Key Population Led Health Services In Thailand Is A Gamechanger
Article – CNS 'Key population led health services (KPLHS) is a bottom-up approach in providing healthcare. It speaks to the needs and willingness of the community which will increase the value of the effort as compared to some thing being given to them passively (top-down … Legalising key population or community-led health services has been a gamechanger in Thailand to protect most-at-risk people from getting infected with HIV, as well as to take evidence-based standard care to the people living with HIV in a person-centred manner so that they can lead normal healthy lives, said Dr Praphan Phanuphak, a legend who has played a defining role in shaping Thailand's HIV response since the first few AIDS cases got diagnosed in the land of smiles in 1985. Key populations are groups of people who are disproportionately affected by HIV (which may include men who have sex with men, transgender women and sex workers, among others). Dr Praphan Phanuphak is a distinguished Professor Emeritus of the Faculty of Medicine, Chulalongkorn University in Bangkok, Thailand. In February 1985, Professor Praphan diagnosed Thailand's first three cases of HIV/AIDS and has been involved in clinical care as well as in HIV prevention and treatment research since then. Together with late Professors Joep Lange and David Cooper, Prof Praphan co-founded HIV-NAT (the HIV Netherlands, Australia, Thailand Research Collaboration), Asia's first HIV clinical trials centre in Bangkok in 1996. Prof Praphan served as the Director of the Thai Red Cross AIDS Research Centre for 31 years (1989-2020) and is currently the Senior Research and Policy Advocacy Advisor of the Institute of HIV Research and Innovation (IHRI) in Bangkok as well as the Advisor of HIV-NAT. Dr Phanuphak was speaking with CNS (Citizen News Service) around 10th Asia Pacific AIDS and Co-Infections Conference (APACC 2025), 2nd Asia Pacific Conference on Point-of-Care Diagnostics for Infectious Diseases (POC 2025) and 13th International AIDS Society Conference on HIV Science (IAS 2025). When people lead, change happens Sterling examples of high impact key population or community-led health service deliver models come from Thailand. HIV key populations continue to play a major role in delivering Pre-Exposure Prophylaxis (PrEP for HIV prevention) to those who are at a heightened risk of HIV acquisition. Thailand has the largest PrEP rollout in Asia Pacific region, 80% of people using PrEP in Thailand receive it from a clinic led and staffed by members of the community that it serves. Key population led health services mean that community thinks, demands and does the work and manages the programmes, for the benefit of their own community members (and the country). This model has proven to help accelerate community-led responses towards ending AIDS with government's support, said Dr Praphan Phanuphak. 'Therefore, it is a collaborative effort with equal responsibility and equal importance [between key populations or communities and the government]. One has to respect the other. It is not that the NGOs are snatching the work or the territory of the government,' he said. 'Key population led health services (KPLHS) is a bottom-up approach in providing healthcare. It speaks to the needs and willingness of the community which will increase the value of the effort as compared to some thing being given to them passively (top-down approach). It fills the gaps that government cannot do and it is acceptable by the community they serve,' emphasised Dr Praphan Phanuphak. However, there could be some misunderstanding from the government side in some instances. For example, some may opine that 'government is getting blamed for not doing enough good work because of which NGOs are trying to compete with them'. Truth is that KPLHS or community-led models are only helping complement government's work. 'One has to show the evidence that KPLHS (key population led health services) can actually provide quality services to the populations that conventional healthcare providers cannot. Key population led health services will lead to ending AIDS and other sustainable health goals beyond HIV, such as mental health and NCDs, i.e., KPLHS is in accordance with government policy,' said Dr Phanuphak. He added: 'KPLHS or key population or community led health services is one arm of the holistic healthcare approach. They need to collaborate with the main stream public healthcare systems. Once the government accepts these facts, legal and financial supports will follow. However, key population led health services may be more expensive than conventional healthcare since the personnels and office facilities are not provided by the government. Therefore, they need enough financial support to ensure sustainability of the programme.' 95-95-95 HIV targets for 2025 Dr Praphan firmly believes that the 95-95-95 HIV goals can be achieved. We have science-based tools to deliver on these goals, he said. 95-95-95 goals refer to ensuring 95% of people living with HIV know their HIV positive status, 95% of them are receiving lifesaving antiretroviral therapy, and 95% of those on treatment are virally suppressed. According to the World Health Organization (WHO), there is ZERO RISK of any further HIV transmission from a person living with HIV whose viral load remains undetectable. That is why it is referred to as Undetectable Equals Untransmittable or #UequalsU. Dr Praphan Phanuphak stresses upon 'finding people with HIV early in all sub-groups of the population.' He calls for focussing on HIV key populations as well as general population too. 'General population is the group currently being left behind since we have rightly focussed on key populations now – but if we are to end AIDS by 2030, we need to reach out to everyone. Each individual – from general population or key population – should have at least one HIV test in their life – earlier the better (and repeat test as appropriate),' he said. 'Pre-Exposure Prophylaxis (PrEP) can prevent up to 99.9% HIV acquisition': Dr Praphan Phanuphak Pre-Exposure Prophylaxis (PrEP) is a medicine taken by those without HIV to reduce the risk of getting infected with the virus. 'PrEP can prevent up to 99.9% of HIV acquisition. One needs to scale up access to PrEP widely and rapidly. Once HIV cannot spread further and individual-at-risk cannot acquire new HIV infection with PrEP use, AIDS can be ended,' said Dr Praphan Phanuphak. Treatment is also prevention because when people with HIV are on treatment and their viral load is undetectable, then there is zero risk of any further HIV transmission. Thailand government rolls out PrEP under its universal health coverage since 2019 onwards. A majority of PrEP is being provided through key population led health services in Thailand. Eliminate legal and structural barriers Dr Praphan calls for eliminating all legal and structural barriers including stigma and discrimination that block access to existing HIV and other health and social support services – especially for HIV key populations. He not only calls for strong and sustained national political commitment which is essential to end AIDS by 2030 but also for accountability of political leaders if we fail to deliver on the promise to end AIDS by 2030. He acknowledges that USA President Trump's current policy decisions have severed research funding and development financing for a range of programmes including HIV in the Global South. 'This could pose to be a big obstacle for ending AIDS in many developing countries,' said Dr Phanuphak. Lot of progress towards ending AIDS but challenges remain Thailand has seen alarmingly high HIV rates in certain sub-national areas or key populations in late 1980s and early 1990s. But a strong community-led response to prevent HIV has turned the tide since then and brought down HIV rates significantly. Thailand today champions a HIV response which parallels only a few other nations in the Global South. And Thailand is on track to deliver on HIV goals for 2025 too. '100% condom use campaign to prevent HIV infection from commercial sex was a game changer. Establishment of HIV-NAT (the HIV Netherlands Australia Thailand Research Collaboration), the first HIV clinical trials centre in Asia to provide free up-to-date HIV treatment through clinical trials in 1996, was another major step forward,' said Dr Praphan Phanuphak. Helping children born to HIV positive parents are HIV free When world's first therapy was rolled out in the rich nations in 1994 to reduce the risk of vertical transmission of HIV (from mother to child), Thailand soon began its rollout two years later (1996 onwards). Zidovudine was the first available antiretroviral agent for reducing mother-to-child HIV transmission in 1994. 'Princess Soamsawali prevention of mother to child transmission of HIV (PMTCT) project was another gamechanger to provide up-to-date PMTCT drugs to all pregnant women in Thailand, free of charge, from 1996 to 2010,' said Dr Praphan Phanuphak. Thailand government took over and provided science-based triple antiretroviral therapy from 2010 to all HIV infected pregnant women so that no child is born of HIV. In 2016, Thailand became the first country in Asian region to eliminate mother to child transmission of HIV as well as syphilis. Another gamechanger which helped Thailand progress towards ending AIDS is generic manufacturing of lifesaving antiretroviral medicines from 2006 onwards. Thailand is a leading manufacturer of generic medicines in the region and also procures lifesaving medicines from other nations including India. Test and treat policy was rolled out in Thailand, a year before the WHO recommendation came in A year before the WHO recommendation came for 'Test and Treat' policy, Thailand had begun its rollout. WHO 'Test and Treat' policy meant that anyone diagnosed with HIV, regardless of their CD4 count or stage of infection, should be offered and immediately linked to lifesaving antiretroviral therapy. Strong scientific evidence showed that this approach maximises the benefits of early treatment for individual health and to prevent further transmission of the virus. What could have gone better in HIV response Dr Praphan Phanuphak reflects and shares that although 'Test and Treat' and PrEP was rolled out by Thailand but it has not been implemented to its full scale. To some extent, it lacks a sense of urgency, and frequent changes of policy makers also impacted the rollout. Flashback to 1980s: When first HIV cases were diagnosed in Thailand by Dr Praphan Phanuphak 'I was accidentally involved in HIV/AIDS arena. I am not an infectious disease doctor, but an allergist and clinical immunologist trained in USA. The first patient, an American gay man living in Thailand, was referred to me at King Chulalongkorn Hospital in October 1984 to investigate the cause of his recurrent muco-cutaneous infection. Immunologic investigations revealed that his T-helper cell numbers and T-cell functions were moderately low, but no diagnosis was made. In February 1985 the patient was admitted into the hospital with confirmed diagnosis of Pneumocystis carinii pneumonia (PCP) and his T-cell numbers and functions were further deteriorated. With the diagnosis of PCP and severe T-cell defect, AIDS was diagnosed at that time,' shared Dr Praphan Phanuphak. He added: 'During the same month, a Thai male sex worker was referred to Chulalongkorn Hospital because of multi-organ cryptococcal infection. His T-cell numbers and T-cell functions were also severely impaired. AIDS was diagnosed in this second patient since he had sexual contact with a foreign man who had sex with men. The girlfriend of this patient was asymptomatic but had generalised lymphadenopathy, Her T-cell numbers and functions were moderately impaired. This patient was counted as the third case. Sera collected from these 3 patients were tested for HIV in May 1985 when the anti-HIV test kit was available in Thailand. All were HIV-positive. These are the first 3 HIV/AIDS cases diagnosed in Thailand, all in February 1985. With the availability of anti-HIV test in Thailand, more and more patients were diagnosed. This accidentally drove me deeper and deeper into the HIV field, coupled with the fact that there were not very many infectious disease doctors in the early days who were willing to see HIV patients.' Dr Phanuphak's lifetime contribution and continuing guidance to shaping HIV responses in Thailand and worldwide is commendable. We hope community-led responses would steer the global AIDS response towards getting on track to end AIDS by 2030. Shobha Shukla – CNS (Citizen News Service) (Shobha Shukla is the award-winning founding Managing Editor and Executive Director of CNS (Citizen News Service) and is a feminist, health and development justice advocate. She is a former senior Physics faculty of prestigious Loreto Convent College and current Coordinator of Asia Pacific Regional Media Alliance for Health and Development (APCAT Media) and Chairperson of Global AMR Media Alliance (GAMA received AMR One Health Emerging Leaders and Outstanding Talents Award 2024). She also coordinates SHE & Rights initiative (Sexual health with equity & rights)


Scoop
2 days ago
- Scoop
Legalising Key Population Led Health Services In Thailand Is A Gamechanger
Legalising key population or community-led health services has been a gamechanger in Thailand to protect most-at-risk people from getting infected with HIV, as well as to take evidence-based standard care to the people living with HIV in a person-centred manner so that they can lead normal healthy lives, said Dr Praphan Phanuphak, a legend who has played a defining role in shaping Thailand's HIV response since the first few AIDS cases got diagnosed in the land of smiles in 1985. Key populations are groups of people who are disproportionately affected by HIV (which may include men who have sex with men, transgender women and sex workers, among others). Dr Praphan Phanuphak is a distinguished Professor Emeritus of the Faculty of Medicine, Chulalongkorn University in Bangkok, Thailand. In February 1985, Professor Praphan diagnosed Thailand's first three cases of HIV/AIDS and has been involved in clinical care as well as in HIV prevention and treatment research since then. Together with late Professors Joep Lange and David Cooper, Prof Praphan co-founded HIV-NAT (the HIV Netherlands, Australia, Thailand Research Collaboration), Asia's first HIV clinical trials centre in Bangkok in 1996. Prof Praphan served as the Director of the Thai Red Cross AIDS Research Centre for 31 years (1989-2020) and is currently the Senior Research and Policy Advocacy Advisor of the Institute of HIV Research and Innovation (IHRI) in Bangkok as well as the Advisor of HIV-NAT. Dr Phanuphak was speaking with CNS (Citizen News Service) around 10th Asia Pacific AIDS and Co-Infections Conference (APACC 2025), 2nd Asia Pacific Conference on Point-of-Care Diagnostics for Infectious Diseases (POC 2025) and 13th International AIDS Society Conference on HIV Science (IAS 2025). When people lead, change happens Sterling examples of high impact key population or community-led health service deliver models come from Thailand. HIV key populations continue to play a major role in delivering Pre-Exposure Prophylaxis (PrEP for HIV prevention) to those who are at a heightened risk of HIV acquisition. Thailand has the largest PrEP rollout in Asia Pacific region, 80% of people using PrEP in Thailand receive it from a clinic led and staffed by members of the community that it serves. Key population led health services mean that community thinks, demands and does the work and manages the programmes, for the benefit of their own community members (and the country). This model has proven to help accelerate community-led responses towards ending AIDS with government's support, said Dr Praphan Phanuphak. "Therefore, it is a collaborative effort with equal responsibility and equal importance [between key populations or communities and the government]. One has to respect the other. It is not that the NGOs are snatching the work or the territory of the government," he said. "Key population led health services (KPLHS) is a bottom-up approach in providing healthcare. It speaks to the needs and willingness of the community which will increase the value of the effort as compared to some thing being given to them passively (top-down approach). It fills the gaps that government cannot do and it is acceptable by the community they serve," emphasised Dr Praphan Phanuphak. However, there could be some misunderstanding from the government side in some instances. For example, some may opine that 'government is getting blamed for not doing enough good work because of which NGOs are trying to compete with them'. Truth is that KPLHS or community-led models are only helping complement government's work. "One has to show the evidence that KPLHS (key population led health services) can actually provide quality services to the populations that conventional healthcare providers cannot. Key population led health services will lead to ending AIDS and other sustainable health goals beyond HIV, such as mental health and NCDs, i.e., KPLHS is in accordance with government policy," said Dr Phanuphak. He added: "KPLHS or key population or community led health services is one arm of the holistic healthcare approach. They need to collaborate with the main stream public healthcare systems. Once the government accepts these facts, legal and financial supports will follow. However, key population led health services may be more expensive than conventional healthcare since the personnels and office facilities are not provided by the government. Therefore, they need enough financial support to ensure sustainability of the programme." 95-95-95 HIV targets for 2025 Dr Praphan firmly believes that the 95-95-95 HIV goals can be achieved. We have science-based tools to deliver on these goals, he said. 95-95-95 goals refer to ensuring 95% of people living with HIV know their HIV positive status, 95% of them are receiving lifesaving antiretroviral therapy, and 95% of those on treatment are virally suppressed. According to the World Health Organization (WHO), there is ZERO RISK of any further HIV transmission from a person living with HIV whose viral load remains undetectable. That is why it is referred to as Undetectable Equals Untransmittable or #UequalsU. Dr Praphan Phanuphak stresses upon "finding people with HIV early in all sub-groups of the population." He calls for focussing on HIV key populations as well as general population too. "General population is the group currently being left behind since we have rightly focussed on key populations now - but if we are to end AIDS by 2030, we need to reach out to everyone. Each individual - from general population or key population - should have at least one HIV test in their life - earlier the better (and repeat test as appropriate)," he said. "Pre-Exposure Prophylaxis (PrEP) can prevent up to 99.9% HIV acquisition": Dr Praphan Phanuphak Pre-Exposure Prophylaxis (PrEP) is a medicine taken by those without HIV to reduce the risk of getting infected with the virus. "PrEP can prevent up to 99.9% of HIV acquisition. One needs to scale up access to PrEP widely and rapidly. Once HIV cannot spread further and individual-at-risk cannot acquire new HIV infection with PrEP use, AIDS can be ended," said Dr Praphan Phanuphak. Treatment is also prevention because when people with HIV are on treatment and their viral load is undetectable, then there is zero risk of any further HIV transmission. Thailand government rolls out PrEP under its universal health coverage since 2019 onwards. A majority of PrEP is being provided through key population led health services in Thailand. Eliminate legal and structural barriers Dr Praphan calls for eliminating all legal and structural barriers including stigma and discrimination that block access to existing HIV and other health and social support services - especially for HIV key populations. He not only calls for strong and sustained national political commitment which is essential to end AIDS by 2030 but also for accountability of political leaders if we fail to deliver on the promise to end AIDS by 2030. He acknowledges that USA President Trump's current policy decisions have severed research funding and development financing for a range of programmes including HIV in the Global South. "This could pose to be a big obstacle for ending AIDS in many developing countries," said Dr Phanuphak. Lot of progress towards ending AIDS but challenges remain Thailand has seen alarmingly high HIV rates in certain sub-national areas or key populations in late 1980s and early 1990s. But a strong community-led response to prevent HIV has turned the tide since then and brought down HIV rates significantly. Thailand today champions a HIV response which parallels only a few other nations in the Global South. And Thailand is on track to deliver on HIV goals for 2025 too. "100% condom use campaign to prevent HIV infection from commercial sex was a game changer. Establishment of HIV-NAT (the HIV Netherlands Australia Thailand Research Collaboration), the first HIV clinical trials centre in Asia to provide free up-to-date HIV treatment through clinical trials in 1996, was another major step forward," said Dr Praphan Phanuphak. Helping children born to HIV positive parents are HIV free When world's first therapy was rolled out in the rich nations in 1994 to reduce the risk of vertical transmission of HIV (from mother to child), Thailand soon began its rollout two years later (1996 onwards). Zidovudine was the first available antiretroviral agent for reducing mother-to-child HIV transmission in 1994. "Princess Soamsawali prevention of mother to child transmission of HIV (PMTCT) project was another gamechanger to provide up-to-date PMTCT drugs to all pregnant women in Thailand, free of charge, from 1996 to 2010," said Dr Praphan Phanuphak. Thailand government took over and provided science-based triple antiretroviral therapy from 2010 to all HIV infected pregnant women so that no child is born of HIV. In 2016, Thailand became the first country in Asian region to eliminate mother to child transmission of HIV as well as syphilis. Another gamechanger which helped Thailand progress towards ending AIDS is generic manufacturing of lifesaving antiretroviral medicines from 2006 onwards. Thailand is a leading manufacturer of generic medicines in the region and also procures lifesaving medicines from other nations including India. Test and treat policy was rolled out in Thailand, a year before the WHO recommendation came in A year before the WHO recommendation came for "Test and Treat" policy, Thailand had begun its rollout. WHO "Test and Treat" policy meant that anyone diagnosed with HIV, regardless of their CD4 count or stage of infection, should be offered and immediately linked to lifesaving antiretroviral therapy. Strong scientific evidence showed that this approach maximises the benefits of early treatment for individual health and to prevent further transmission of the virus. What could have gone better in HIV response Dr Praphan Phanuphak reflects and shares that although "Test and Treat" and PrEP was rolled out by Thailand but it has not been implemented to its full scale. To some extent, it lacks a sense of urgency, and frequent changes of policy makers also impacted the rollout. Flashback to 1980s: When first HIV cases were diagnosed in Thailand by Dr Praphan Phanuphak "I was accidentally involved in HIV/AIDS arena. I am not an infectious disease doctor, but an allergist and clinical immunologist trained in USA. The first patient, an American gay man living in Thailand, was referred to me at King Chulalongkorn Hospital in October 1984 to investigate the cause of his recurrent muco-cutaneous infection. Immunologic investigations revealed that his T-helper cell numbers and T-cell functions were moderately low, but no diagnosis was made. In February 1985 the patient was admitted into the hospital with confirmed diagnosis of Pneumocystis carinii pneumonia (PCP) and his T-cell numbers and functions were further deteriorated. With the diagnosis of PCP and severe T-cell defect, AIDS was diagnosed at that time," shared Dr Praphan Phanuphak. He added: "During the same month, a Thai male sex worker was referred to Chulalongkorn Hospital because of multi-organ cryptococcal infection. His T-cell numbers and T-cell functions were also severely impaired. AIDS was diagnosed in this second patient since he had sexual contact with a foreign man who had sex with men. The girlfriend of this patient was asymptomatic but had generalised lymphadenopathy, Her T-cell numbers and functions were moderately impaired. This patient was counted as the third case. Sera collected from these 3 patients were tested for HIV in May 1985 when the anti-HIV test kit was available in Thailand. All were HIV-positive. These are the first 3 HIV/AIDS cases diagnosed in Thailand, all in February 1985. With the availability of anti-HIV test in Thailand, more and more patients were diagnosed. This accidentally drove me deeper and deeper into the HIV field, coupled with the fact that there were not very many infectious disease doctors in the early days who were willing to see HIV patients." Dr Phanuphak's lifetime contribution and continuing guidance to shaping HIV responses in Thailand and worldwide is commendable. We hope community-led responses would steer the global AIDS response towards getting on track to end AIDS by 2030. Shobha Shukla – CNS (Citizen News Service) (Shobha Shukla is the award-winning founding Managing Editor and Executive Director of CNS (Citizen News Service) and is a feminist, health and development justice advocate. She is a former senior Physics faculty of prestigious Loreto Convent College and current Coordinator of Asia Pacific Regional Media Alliance for Health and Development (APCAT Media) and Chairperson of Global AMR Media Alliance (GAMA received AMR One Health Emerging Leaders and Outstanding Talents Award 2024). She also coordinates SHE & Rights initiative (Sexual health with equity & rights)


NZ Herald
3 days ago
- NZ Herald
Gilead's twice-a-year HIV prevention shot wins regulatory approval in US
Gilead Sciences Inc said it won United States approval from Food and Drug Administration regulators for a drug to prevent HIV that only has to be given twice a year. That makes it a convenient new way to ward off infection in a wide range of people. In two